Kovaltry Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to safety concerns with plasma derived factors, improved recombinant technology, rising diagnosis of hemophilia a, expansion of treatment centers, better patient survival rates.

The growth in the forecast period can be attributed to increasing adoption of prophylaxis therapy, growth in home infusion programs, improved access in emerging markets, continued innovation in recombinant factors, stable demand for standard rfviii therapies. Major trends in the forecast period include shift toward recombinant factor viii therapies, expansion of prophylactic hemophilia a treatment, focus on infection free clotting factor products, growth of home based hemophilia management, personalized dosing regimens in bleeding disorders.

The rise in the prevalence of hemophilia is projected to significantly drive the growth of the Kovaltry market. Hemophilia is a rare, inherited bleeding disorder in which blood does not clot properly due to a deficiency or absence of specific clotting factors, primarily factor VIII or IX. The increasing prevalence of hemophilia can be attributed to factors such as genetic mutations, better awareness and diagnosis, and advancements in medical technologies that enable improved detection and reporting of the condition. Kovaltry plays a key role in managing hemophilia by providing consistent and adequate clotting factor replacement, helping to minimize bleeding episodes. It supports long-term management of the condition, improving the quality of life for patients and reducing the risk of complications. For example, in June 2024, the Australian Bleeding Disorders Registry, an Australian government agency, reported that the total number of patients with hereditary hemophilia in the country rose to 8,034 in 2024, up from 7,850 in 2022. This increase in prevalence is contributing to the growing demand for Kovaltry.

The rise in the aging population is expected to significantly drive the growth of the Kovaltry market in the future. The aging population is increasing due to factors such as improved life expectancy, declining birth rates, and advancements in healthcare that have led to greater longevity. As people age, they may face heightened risks of bleeding due to age-related changes in health, including vascular conditions and a weakened ability to maintain effective clotting. Kovaltry is particularly important for managing bleeding episodes in older individuals with hemophilia A, helping to prevent complications and improve quality of life. For example, in July 2023, Age UK, a UK-based charity for older individuals, reported that there were 11 million people aged over 65 in England in 2023. This number is expected to rise by 10% over the next five years and by 32% by 2043, equating to an increase of 1.1 million and 3.5 million individuals, respectively. As a result, the growing aging population will play a pivotal role in driving the demand for Kovaltry.

The increasing focus on personalized medicine is also expected to propel the Kovaltry market. Personalized medicine is an approach that tailors treatment and preventive strategies to individual patients based on their genetic, environmental, and lifestyle factors. The rising focus on personalized medicine is driven by advancements in genomics and biotechnology, greater awareness, regulatory support, and the shift toward value-based healthcare models. This focus is particularly important for Kovaltry, as personalized medicine allows for tailored treatment plans that optimize dosing and therapeutic outcomes for hemophilia A patients. By leveraging genetic profiling and individualized care, Kovaltry enhances the effectiveness of treatments and improves patient satisfaction. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from the six approvals in 2022. As a result, the growing emphasis on personalized medicine is driving the Kovaltry market forward.

Major companies operating in the kovaltry market are Bayer HealthCare LLC.

North America was the largest region in the kovaltry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kovaltry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kovaltry market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the kovaltry market by increasing costs related to recombinant protein manufacturing inputs and cold chain logistics. Hemophilia treatment centers and hospitals in import dependent regions face higher procurement costs. These impacts may influence therapy pricing and reimbursement negotiations. However, tariffs are encouraging regional biologics manufacturing investments. This supports long term availability of essential clotting factor therapies.

The kovaltry market research report is one of a series of new reports that provides kovaltry market statistics, including kovaltry industry global market size, regional shares, competitors with a kovaltry market share, detailed kovaltry market segments, market trends and opportunities, and any further data you may need to thrive in the kovaltry industry. This kovaltry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kovaltry is a recombinant factor VIII (rFVIII) therapy used to treat and prevent bleeding episodes in individuals with hemophilia A, a genetic disorder caused by a deficiency in clotting factor VIII. Manufactured using recombinant DNA technology, Kovaltry is free from human- or animal-derived proteins, which reduces the risk of infections. It is administered intravenously, and its dosage and frequency are tailored to each patient based on their weight, the severity of factor VIII deficiency, and specific clinical needs.

The main formulations of Kovaltry include injectable formulations, such as lyophilized powder and ready-to-use solutions. Injectable formulations are designed to be administered through intravenous injection, ensuring rapid absorption and effectiveness. Kovaltry is indicated for the treatment of hemophilia A, its prophylaxis, and the management of bleeding episodes. It is used by a wide range of patient demographics, including pediatric, adult, and geriatric patients. The distribution channels for Kovaltry include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. It is utilized by various healthcare providers such as hospitals, hemophilia treatment centers, specialty clinics, and home healthcare providers.

The kovaltry market consists of sales of recombinant factor VIII therapy, infusion devices, patient support kits, prophylactic treatment products, and combination kits and ancillary products. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.